Abstract | OBJECTIVE: DESIGN: Controlled, in vivo laboratory study. SETTING: Research laboratory of a health sciences university. SUBJECTS: C57BL/6 mice. INTERVENTIONS: MEASUREMENTS AND MAIN RESULTS: Soluble receptor for advanced glycation end products-treated mice demonstrated an enhanced bacterial dissemination to liver and lungs, accompanied by increased hepatocellular injury and exaggerated systemic cytokine release, 20 hrs after intraperitoneal administration of Escherichia coli. Soluble receptor for advanced glycation end products administration in healthy, uninfected mice did not induce an immune response. Remarkably, lung inflammation was unaffected. Furthermore, high-mobility group box 1 release was enhanced during peritonitis and anti-high-mobility group box 1 treatment was associated with higher bacterial loads in liver and lungs. CONCLUSIONS:
|
Authors | Marieke A D van Zoelen, Ahmed Achouiti, Ann-Marie Schmidt, Huan Yang, Sandrine Florquin, Kevin J Tracey, Tom van der Poll |
Journal | Critical care medicine
(Crit Care Med)
Vol. 38
Issue 6
Pg. 1414-22
(Jun 2010)
ISSN: 1530-0293 [Electronic] United States |
PMID | 20386310
(Publication Type: Journal Article)
|
Chemical References |
- Chemokines
- HMGB1 Protein
- Ligands
- Receptor for Advanced Glycation End Products
- Receptors, Immunologic
|
Topics |
- Animals
- Chemokines
(metabolism)
- Disease Models, Animal
- Escherichia coli Infections
(immunology, metabolism, pathology)
- Female
- HMGB1 Protein
(administration & dosage, physiology)
- Immunity, Innate
(physiology)
- Infusions, Parenteral
- Ligands
- Liver
(metabolism, microbiology, pathology)
- Lung
(metabolism, microbiology, pathology)
- Mice
- Mice, Inbred C57BL
- Neutrophil Infiltration
- Peritonitis
(immunology, metabolism, pathology)
- Receptor for Advanced Glycation End Products
- Receptors, Immunologic
(administration & dosage, immunology)
- Sepsis
(immunology, metabolism, pathology)
|